The FDA has approved a change to the prescribing information for Vyvanse (lisdexamfetamine dimesylate capsules, from Shire). The updated labeling now includes supplemental data demonstrating ...

Once-daily drug may now be used in children between 13 and 17 years of age. FDA has sanctioned Shire’s Vyvanse® Capsules CII for the treatment of attention deficit hyperactivity disorder (ADHD) in ...

Shire plcSHPG announced that it has updated Vyvanse's label to include data associated with its supplemental New Drug Application (sNDA) for the treatment of adults with moderate-to-severe binge ...

Vyvanse (lisdexamfetamine) is a prescription drug that’s one of the first-choice medications for treating attention deficit hyperactivity disorder (ADHD). It is also used to treat binge eating ...

Shire announced positive top-line results from a Phase 3 study of Vyvanse (lisdexamfetamine dimesylate) Capsules (CII) in adults with moderate-to-severe binge eating disorder (BED). SPD489-346 was ...

To hear Shire ($SHPG) tell it, there aren't many adequate and well-controlled drug studies in preschool-aged children with ADHD. But never fear, the company says: It ...

Fidgeting, restlessness, inattention—all are symptoms of attention deficit/hyperactivity disorder. So it may seem counterproductive (to say the least) to take a stimulant to manage ADHD. But that's ...